Compugen’s anti-PVRIG patent upheld by the EPO

18-07-2023

Marisa Woutersen

Compugen’s anti-PVRIG patent upheld by the EPO

Chris Redan / Shutterstock.com

Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.


European Patent Office, patent, Compugen, GSK, immunotherapy, Cancer Research UK, Anat Cohen-Dayag, Markus Rieck, Fuchs Patentanwälte Partnerschaft

LSIPR